# CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer

> **NCT03374852** · PHASE2 · WITHDRAWN · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University**

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** CPI-613
- **DRUG:** mFOLFIRNOX

## Key facts

- **NCT ID:** NCT03374852
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-08
- **Primary completion:** 2019-10-05
- **Final completion:** 2020-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI Left institution on 8/6/2018 and study has been final reported with IRB. Never opened to accrual
- **Last updated:** 2025-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03374852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03374852, "CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03374852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*